The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Truro, yes I know it's a guess, but as I said the company is giving no visibility on this, so answer the question. They are quite happy to announce "record revs" which don't need to be above a million after 20 years which is pretty embarrassing stuff, so I would think that if they were confident on making a profit next year they'd be shouting it from the rooftops wouldn't they? Wouldn't a company hat feels it is going to be profitable look for broker coverage?
Also, please refrain from making personal attacks on posters. If you are confident about this share there is no reason you can't present your logical thought process.
Truro - Just report the poster - They've admitted they don't hold so are just disruptive to the board and have mocked mental health.
Re-read my post share4 and then comprehend it. You ask nonsensical and foolish questions. You might need to look up 'guess' in a dictionary.
Truro, if PYC are expected to break into profit next year why aren't they announcing that? Where's the broker forecasts?
Great for you share4 to follow.
https://www.linkedin.com/company/physiomics-plc
108459
Thanks invester1978. Good to see positive well constructed posts on here. Puts a lot of thoughtful background on our current situation which I for one think is in the best position we have ever been in. My guess is that next financial year we will break into profit, which, if the commercial deal with VAL comes through could be meaningful. Thanks again.
Did you read the interim results?
Cash and cash equivalents of £794k at 31 December 2021 (31 December 2020: £1.15m)
You say they've only burned 5k?
Also matie, you were quite sure DMTR was going to make lots of profit, did it?
Well junior miners are completely different, it owns assets worth 12p with future profits in the tens of millions, hence why I bought them at 0.7p and it's now 1.2p. Not sure what PYC has to make it particularly profitable, the same tech it's not been able to sell for a profit.
Q: You mentioned Project Optimus in your last presentation. Could you please elaborate on this?
Well, just to remind everyone that Project Optimus is an FDA initiative aimed at helping companies developing drugs to focus more on the personalisation of dosing. So, although I don’t think it’s an initiative we would necessarily directly engage with, it’s certainly a clear signal that regulators are interested in how companies come to decisions about dosing in clinical trials. It’s certainly a key driver of the interest by our clients in engaging with mathematical modelling and specifically with us in the field of oncology to provide some weight behind and quantification of the decisions that they’re making on trial design, specifically in relation to dosing and scheduling decisions that have been made on a more heuristic basis in the past. If you go back 20 or 30 years in pharmaceutical industries, the way in which people calculated initial human doses was really just based on very simple algorithms, whereas now we’re able to bring to bear far more sophisticated tools and this is becoming an expectation. As a result I think the market for this sort of activity is going to continue to grow.
Pyc has tiny cash burn. . In the full year ended 30 June 2021 our net change in cash was a reduction of just ~£5k. In each of the last two full financial years we’ve maintained cash and equivalents of over £1m.
Hi matie, question on KEFI are they anywhere near profitable like PYC is? ?? are they invested in Ethiopian war zone asking for a friend ??
Actions > Words. They have many clients are have been unable to profit from them.
Q: Can we say how long we’ve been in discussion with the potential new big pharmaceutical client?
We’ve been in discussion with them for over 12 months, and that is common for big pharma clients. They take a long time to bring on board, but once you once you’ve got through all of their myriad procurement processes as well as the commercial negotiation around the contract then, with a following wind, they can turn out to be a client like Merck. So the opportunity is significant. It’s the sort of investment of time that, as a CEO or head of business development, you never mind making. As I said in our interims RNS, we are in in in advanced discussions with the company and we’ll say more as soon as we’re able to.
Q: Could you comment on your work or involvement with Merck KGaA?We’ve been engaged with Merck for many years, even before I arrived in the Company. As you will recall shortly after my arrival in the Company in around December 2017 we signed our first umbrella agreement with Merck where they aspired to spend at least €500,000 with us annually. I’m proud to say that we’ve done at least that every year since then. It’s not guaranteed and yet they’ve come back for more on a regular basis. Our close relationship has survived management changes and reorganisations and importantly our relationship with them today, I believe, is the best it’s ever been. Our work provides a key input to a number of important decisions they make relating to their active clinical programs and that makes me very proud. This relationship is a very real validation of our Virtual Tumour platform. Q: Is there any particular reason for the value of contracts remaining undisclosed?We can’t always disclose both the identity of our client and the value of the contract because they won’t let us. In my view, it’s more important for our shareholders and other stakeholders to understand who it is that we’re working with and what we’re doing rather than announce that we have a contract with an undisclosed pharmaceutical or biotech Company, because that sort of announcement never feels very satisfying and generally means that we can’t then really talk in any detail about what we’re doing with that client. I believe the value of being able to disclose the identity of clients is greater than the value of just disclosing the contract size. Where we’re required to disclose for reasons of compliance with regulations, then then we do so.
Q: What competitive advantage does Physiomics have?
That’s a great question. We have several. On the one hand, we are a specialist in oncology mathematical modelling, and there are few companies out there that can say that with their hand on heart. We have competitors that do mathematical modelling who tend to be generalists. We have competitors that focus on oncology, but they don’t tend to be specialists in modelling. So I believe the confluence of those two things is a position where we have a unique market opportunity. The second thing I would say is our people and our experience are really second to none. They work hard, they’re smart and they’re universally well respected by the clients that we take on. I also believe that we’re making genuinely important contributions to the R&D efforts of the clients that that we work with, and that has led to a significant boost in our reputation.
When I arrived at the Company 5-6 years ago, we were fairly little known other than amongst a small circle of clients that we’d been working with for a while. Now we’re getting referrals; people that we work with, talk to their friends and literally relatives sometimes, and we get phone calls from those individuals who may be working in in other companies. We’ve had several projects commissioned in this way, and this is extremely gratifying. I think it’s a real demonstration that what we do makes a difference and that our clients continue to value that.
Q: Please say a few words on the current pipeline?
The pipeline is genuinely the strongest it’s ever been. For the first time, we’ve really been able to quantify that by disclosing that we have contracted revenue of over £460,000 for this half that we’re in now. We’ve never been able to say that before. We’ve never had that degree of visibility for the next five months. And obviously that’s just the revenues that we have signed up at this point in time.
Above these contracted revenues in the pyramid of Business Development we have a number of contracts that are in discussion, one of which is with another big pharma Company. If we can clinch that one, that is another very exciting opportunity and could be a big step forward for the Company. But it’s not the only opportunity. We now have a more rigorous process for categorising the different opportunities thanks to our new BD lead. While this isn’t something that I can explain in a few words, I can assure you that at every stage within that BD funnel we now looking stronger than I think we ever have done before.
More good news today... VAL201 and DoseMeRX still in the pipeline ;-)
Those that doubt PYC... It's Friday treat yourself to a pint of bitter...
No contract value always a negative.
https://twitter.com/aiminvestor1978/status/1512310852925415426?s=21&t=5QXHZ7WS8EkypwLWGsXgUg
With more to come…. Tabula Rasa , Val201 and the large pharmaceutical client etc
Dec 2021
13th Further £300k with Merck for DNA repair work with more to follow
" there is no other company with Physiomics' experience in the field of DDR modelling"
23rd Follow up contract with Numab pharmaceutical
Feb 2022
Exploring more commercial deals with Tabula Rasa HealthCare now that PYC tech has been fully embedded
March 2022
New contract with USA client
Confirmation of record H1 revenues and record order book for H2 + discussions with new large pharma client
April 2022
New contract with French HQ client called Servier who are one of France's leading pharmaceutical companies with a truly global outlook
No they aren't
More than half the posts today have been deleted as are all of Wednesday's posts Are people getting that worried that the share price is going to sink now that the resident ramper has upped sticks? Are the 100k sells him closing his position?
TheoremRx need funding, any particular reason for the delay?